Marc Stapley, director of Glaukos Corporation (NYSE: GKOS)executed a direct sale of 15,000 shares for a transaction value of approximately $1.9 million on January 22, 2026, following the exercise of an equivalent number of stock options, according to a Presentation of form 4 of the SEC.

Transaction value based on SEC Form 4 weighted average purchase price ($127.71); post-transaction value based on the closing price on January 22, 2026 ($125.90).

• How does the size of this transaction compare to Marc Stapley’s previous dispositions?
  This sale of 15,000 shares substantially exceeds the average administrative disposition of 6,250 shares since May 2024.

• What was the structural context behind the transaction?
  The disposition resulted from a derivative event: 15,000 stock options were exercised and the underlying shares were immediately sold, as disclosed in the derivatives context of the filing.

• What is the broader implication for Stapley’s property and future capacity?
  After this transaction, direct holdings fell to 37,449 shares (valued at ~$4.71 million on the day of the trade), representing 0.07% of the outstanding shares, and no outstanding options.

* 1-year price change calculated from January 31, 2026.

Glaukos Corporation offers ophthalmic medical devices and pharmaceutical therapies, specializing in solutions for glaucoma and related eye conditions. His clients include ophthalmologists and healthcare institutions in the United States and internationally, focusing on patients with mild to moderate open-angle glaucoma and related conditions.

On January 28, 2026, Glaukos announced that it received FDA approval for the re-administration of one of its supplements to help glaucoma patients manage their condition. Now, doctors can re-administer the supplement to patients more than once, depending on the condition of their corneas. The company remains a dominant force in a pharmaceutical market facing strong demand for products related to eye health.

It should also be noted that the trades that Stapley made were scheduled in advance under a Rule 10b5-1 trading plan, which allows an insider to set up trades for future dates.

Glaukos shares had a rough 2025, falling roughly 25% for the year. However, shares are up 4.3% in January 2026 and the recent FDA approval may help share prices in the near term. But in the long run, the company has been operating at a zero profit level for more than five years and is on track to close fiscal year 2025 with a net loss again.

Ever feel like you’ve missed the boat on buying the hottest stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock. recommendation for companies that believe they are about to exit. If you’re worried that you’ve already missed your investment opportunity, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled in 2009, you would have $495,739!*

• Apple: if you invested $1,000 when we doubled in 2008, you would have $49,363!*

• Netflix: if you invested $1,000 when we doubled in 2004, you would have $450,256!*

Right now, we’re issuing “Double Down” alerts for three amazing companiesavailable when you join Stock advisorand there may not be another opportunity like this anytime soon.

See the 3 actions »

* Stock Advisor returns from January 26, 2026

Ade Hennis has no position in any of the aforementioned stocks. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has one disclosure policy.

Director sells 15,000 shares of GKOS for $1.9 million was originally published by The Motley Fool